Mylan (NASDAQ:MYL) has been given a $53.00 price target by JPMorgan Chase & Co. in a report issued on Friday. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 25.77% from the stock’s current price.
MYL has been the subject of a number of other research reports. BidaskClub downgraded shares of Mylan from a “strong-buy” rating to a “buy” rating in a report on Friday, January 26th. Susquehanna Bancshares reissued a “positive” rating and issued a $55.00 price objective (up previously from $47.00) on shares of Mylan in a research note on Thursday, January 25th. Zacks Investment Research raised shares of Mylan from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Guggenheim initiated coverage on shares of Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 price objective for the company. Finally, Wells Fargo & Co set a $43.00 price objective on shares of Mylan and gave the stock a “hold” rating in a research note on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the stock. Mylan currently has a consensus rating of “Buy” and a consensus price target of $44.89.
Mylan (MYL) opened at $42.14 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. Mylan has a 1-year low of $29.39 and a 1-year high of $47.82. The company has a market cap of $22,610.00, a PE ratio of 25.39, a P/E/G ratio of 1.14 and a beta of 1.35.
In other news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.69% of the company’s stock.
Large investors have recently modified their holdings of the company. Meeder Asset Management Inc. increased its position in shares of Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after acquiring an additional 1,475 shares during the period. BT Investment Management Ltd purchased a new position in shares of Mylan during the third quarter worth approximately $142,000. Rational Advisors LLC purchased a new position in shares of Mylan during the fourth quarter worth approximately $190,000. First Personal Financial Services increased its holdings in Mylan by 77.1% during the fourth quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after buying an additional 2,106 shares during the period. Finally, Lombard Odier Asset Management Europe Ltd purchased a new position in Mylan during the fourth quarter valued at approximately $209,000. 75.56% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Mylan (MYL) Given a $53.00 Price Target by JPMorgan Chase & Co. Analysts” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/18/mylan-myl-given-a-53-00-price-target-by-jpmorgan-chase-co-analysts.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.